Human glial chimeric mice reveal astrocytic dependence of JC virus infection

Yoichi Kondo,1,2 Martha S. Windrem,1,2 Lisa Zou,1 Devin Chandler-Militello,1 Steven J. Schanz,1 Romane M. Auvergne,1 Sarah J. Betstadt,3 Amy R. Harrington,4 Mahlon Johnson,4 Alexander Kazarov,5 Leonid Gorelik,5 and Steven A. Goldman1,2,6

1Center for Translational Neuromedicine, 2Department of Neurology, 3Department of Obstetrics and Gynecology, and 4Department of Pathology, University of Rochester, Rochester, New York, USA. 5Biogen Idec Inc., Cambridge, Massachusetts, USA. 6Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease triggered by infection with the human gliotropic JC virus (JCV). Due to the human-selective nature of the virus, there are no animal models available to investigate JCV pathogenesis. To address this issue, we developed mice with humanized white matter by engrafting human glial progenitor cells (GPCs) into neonatal immunodeficient and myelin-deficient mice. Intracerebral delivery of JCV resulted in infection and subsequent demyelination of these chimeric mice. Human GPCs and astrocytes were infected more readily than oligodendrocytes, and viral replication was noted primarily in human astrocytes and GPCs rather than oligodendrocytes, which instead expressed early viral T antigens and exhibited apoptotic death. Engraftment of human GPCs in normally myelinated and immunodeficient mice resulted in humanized white matter that was chimeric for human astrocytes and GPCs. JCV effectively propagated in these mice, which indicates that astroglial infection is sufficient for JCV spread. Sequencing revealed progressive mutation of the JCV capsid protein VP1 after infection, suggesting that PML may evolve with active infection. These results indicate that the principal CNS targets for JCV infection are astrocytes and GPCs and that infection is associated with progressive mutation, while demyelination is a secondary occurrence, following T antigen–triggered oligodendroglial apoptosis. More broadly, this study provides a model by which to further assess the biology and treatment of human-specific gliotropic viruses.

Introduction

Progressive multifocal leukoencephalopathy (PML) is a demyelinating condition characterized by the degenerative loss of cerebral white matter after infection by JC virus (JCV; also known as JCPyV), a normally latent polyoma virus that becomes virulent in the setting of immunosuppression (1, 2). JCV is gliotropic and associated with oligodendrocytic loss in humans, but the human-selective nature of its infectivity and glial pathology has prevented the establishment of informative animal models of PML. As a result, prior studies have focused on modeling the systemic spread of JCV infection in mice with humanized immune systems (3) and in mice in which preinfected cells were delivered to the brain (4), but no experimental studies have yet achieved infection of the adult CNS by JCV or permitted modeling of the progressive demyelination of PML. On that basis, we asked whether mice neonatally engrafted with human glial progenitor cells (GPCs), whose forebrain glial populations become substantially humanized with age, might be able to support JCV infection and manifest the clinical hallmarks of PML, white matter gliosis and demyelination. We therefore engrafted newborn immunodeficient and myelin-deficient homozygous shiverer (Rag2−/−Mbpsh/−) mice with bipotential GPCs isolated from fetal human brain tissue, thereby generating human glial-chimeric mouse brains (5, 6).

The donor human GPCs with which these mice were engrafted were bipotential oligodendrocyte-astrocyte progenitor cells, identified by their expression of CD140a (also known as PDGFRα) as well as by gangliosides and chondroitin sulfate proteoglycans recognized by the A2B5 and NG2 antibodies, respectively. In the neonatal mouse brain environment, the human GPCs preferentially expand and broadly migrate, so that over a several-month period postnatally, most murine glia are replaced by human glia, including astrocytes and their progenitors, as well as oligodendrocytes when congenitally hypomyelinated recipients are used as hosts (7). These mice develop a largely humanized glial environment; in particular, Rag2−/−Mbpsh/− mice develop entirely humanized central myelin. We postulated that the effective glial humanization of these mice might permit their productive in vivo infection by cell type– and species-specific human gliotropic viruses. To address this hypothesis, once our human glial chimeric Rag2−/−Mbpsh/− mice grew to maturity, we injected them intracerebrally with live JCV of several distinct virulent strains, including type 1A (referred to herein as Mad-1 JCV) and the type 2A JCV archetype, and several patient-isolated mutant isoforms thereof (8). We then assessed the consequent JCV infection of GPCs, astrocytes, and oligodendrocytes using immunolabeling for both early viral T antigen (T-Ag) and VP1 capsid protein.

The JCV-injected human glial chimeric Rag2−/−Mbpsh/− mice developed widespread infection of their integrated human glia,
and this process was accompanied by local demyelination in association with regions of frank gliosis. The resultant humanized rodent model of JCV infection allowed us to then ask a number of hitherto unapproachable questions regarding the genesis of PML. What is the phenotypic selectivity of JCV infection in vivo? Are oligodendrocytes indeed the principal target phenotype of the virus? What is the principal reservoir of infection? What are the kinetics of temporal spread of the virus? Using what cellular hosts, and by what anatomic pathways, does it propagate and spread? Is the virus genetically stable during replication in the host? Does infectivity vary by viral genotype? Beyond addressing these questions in vivo, we also infected cultures of human fetal GPCs and their progeny with JCV in order to assess the cellular mechanisms of JCV toxicity as concurrent functions of time, cell cycle, and phenotype. We found that the principal targets of JCV were GPCs and astrocytes; that oligodendroglia were also infected, but later and less efficiently; that the virus actively mutated with viral spread; and, most remarkably, that infected oligodendroglia were not even necessary for viral propagation and spread. Our data thus indicate that JCV is principally a disease of astrocytes and their progenitors, with oligodendrocytic loss and demyelination a pathogenic but unnecessary concomitant to viral infection and spread.

Results

JCV efficiently infects astroglia and their progenitors in culture. Although PML has traditionally been viewed as a disease of oligodendrocytes, both astrocyte and GPC infection have been reported in vitro (9–13). Therefore, we first sought to assess the phenotypic selectivity of viral infection and propagation among the different phenotypes of human macroglia. We used either A2B5-directed immunoselection after PSA-NCAM depletion or CD140a-targeted selection to isolate human GPCs from second-trimester fetal human brain. The resultant isolates were then aliquoted, with some cultures maintained as human GPCs in serum-free media supplemented with FGF2 and PDGF, while others were switched to tri-iodothyronine (T3) to bias oligodendroglial differentiation. In parallel, CD44-based immunomagnetic sorting was used to select phenotypically restricted astroglia from matched samples. After at least 1 week in vitro, cultures of each phenotype were separately exposed to either JCV or vehicle control. At 3, 5, or 10 days thereafter, the cultures were immunostained for T-Ag or VP1 (n = 4 experiments per marker per time point). At least 2,000 cells in total were analyzed for each phenotype at each time point (>500 cells in n = 4 human samples per experimental group). In the JCV-exposed CD140a- and CD44-sorted cultures, both CD140a+ human GPCs and glial fibrillary acidic protein-expressing (GFAP+) astrocytes, respectively, were infected quickly and efficiently. Within days, each manifested robust expression of both early viral T-Ag and VP1 (Figure 1, A and B), neither of which was detected in vehicle controls. In contrast to the rapid course of astrogial infection, oligodendrocytic infection in vitro was delayed and initially of relatively low efficiency (Figure 1C; see Supplemental Figure 1 for individual immunolabels; supplemental material available online with this article; doi:10.1172/JCI76629DS1). At both 3 and 5 days postinfection (DPI), the incidence of T-Ag infection was significantly higher in cultured astrocytes than in oligodendrocytes (P < 0.01, 2-way ANOVA with Bonferroni post-hoc comparisons). VP1-defined viral replication was also significantly less common in oligodendroglia than in astrocytes at 3 and 5 DPI (P < 0.01, 2-way ANOVA with Bonferroni post-hoc comparisons); indeed, VP1+ oligodendroglia were rarely noted in the first week after infection. Nonetheless, by 10 DPI, significant numbers of VP1+ oligodendroglia appeared as well, following the delayed rise in T-Ag-associated oligodendroglial infection (Figure 1, C–E). In astrocytes and oligodendrocytes alike, VP1-defined viral replication was associated with significant increments in nuclear size and DNA content (Supplemental Figure 2).

JCV initially infects astroglia in vivo. Since astrocystic infection was surprisingly more robust than that of oligodendrocytes in vitro, we next sought to define the relative phenotype-selective tropism and infectivity of JCV in vivo. Since JCV infects only human glia, we established human glial chimeric mice so as to provide an in vivo model for JCV infection and JCV-dependent demyelination. We injected neonatal Rag2−/−Mbpshi/shi mice with 2 × 10^5 human GPCs, delivered as 10^5 cells/hemisphere in 2 intracallosal injections per side of 5 × 10^5 cells each. Myelination by neonatally engrafted human GPCs has been well characterized in human glial chimeric Rag2−/−Mbpshi/shi mice, which first achieve dense callosal and capsular myelination only after 3 months of age (6, 14). As a result, we assessed the effects of JCV in Rag2−/−Mbpshi/shi mice first injected with virus at 2, 3, or 4 months of age (n = 5, 10, and 3, respectively). At those time points, we delivered Mad-1 (type 1A) JCV to the human glial chimeras by stereotaxic intracallosal injection. The animals (n = 18 total) were all killed at 20 ± 1 weeks of age, i.e., at 3–4, 6–8, or 11–12 weeks after infection (n = 3, 10, and 5, respectively). Their brains were then assessed for both early and late JCV antigens, as well as for cellular pathology and myelin integrity (see Supplemental Table 1 for details of all mice assessed histologically).

We found that JCV induced the expression of the major early and late viral gene products (T-Ag and the VP1 capsid protein, respectively) in oligodendrocytes, astrocytes, and GPCs throughout the chimeric Rag2−/−Mbpshi/shi corpus callosum (Figure 2A). Infected astrocytes and GPCs were often magnocellular, with overtly enlarged nuclei, while processes of infected astrocytes manifested a bizarre fibrotic morphology (Figure 2B), as described previously in human PML (15). In contrast, at these early time points, relatively few infected myelin basic protein-expressing (MBP) oligodendroglia were noted, most of which expressed T-Ag rather than VP1 (Figure 2C and see below), suggestive of both relatively later infection and less viral replication compared with astrocytes. Importantly, infection was restricted to human cells; no murine cells expressed either early or late viral genes, and nonchimeric, engrafted mouse controls manifested no evidence of infection after JCV injection (Figure 2D).

JCV infection in vivo results in demyelination of human chimeric white matter. To better understand the means by which demyelination occurs in JCV infection, we next examined the myelination of JCV-infected human glial chimeric Rag2−/−Mbpshi/shi mouse brains. By 4 weeks after JCV infection, focal regions of demyelination and infection-associated astrogliosis were noted in the forebrain white matter of infected mice, typically in discrete foci abutting the callosal and fimbrial walls of the lateral ventricle (Figure 3, A and B). Importantly, while areas of demyelination were associated
tors, as cellular expression of the VP1 capsid protein, which is expressed by mature postreplicative virions, was largely limited to astroglia and GPCs. Thus, astrocytes and GPCs may be the principal reservoirs for intracerebral viral propagation. In contrast, VP1+ human oligodendrocytes were uncommon, and inevitably appeared dying or pyknotic (Figure 2A); most infected oligodendroglia that could be identified as such in vivo were T-Ag+, but VP1+. This finding indicated that oligodendroglia are initially infected, but die or are lost before the VP1-identifiable completion of viral replication.

JCV infection in vivo spreads in different cell types at different rates. As a result of the human-selective nature of JCV infection, and the lack of early or phenotype-specific radiographic surrogates, the dynamics of viral propagation in the infected CNS remain unknown. We thus investigated the pattern of JCV spread in human glial chimeras, as a function of time after infection. We tracked the expansion and spread of both infected glia and of the fraction harboring replicating virus by immunostaining for T-Ag and VP1, respectively. Both T-Ag+ and VP1+ human cells were progressively more numerous and widespread as a function of time after infection, with infection progressing from the site of viral injection at 4 weeks to include much of the central white matter at 12 weeks (Figure 4A). Notably, despite ample evidence of astrocytic viral replication, as defined by VP1 expression, by astrocytes and GPCs alike (Figure 4, B, D, and E), a high proportion of T-Ag+ glia remained viable but VP1+. Indeed, the ratio of T-Ag+ glia to VP1+ glia increased with time over the 12-week observation period (Figure 4B), suggestive of an accelerated rate of infection. While these T-Ag+VP1+ infectants included oligodendrocytes, most were astroglial; both the density and relative proportions of T-Ag+MBP+ oligodendrocytes were significantly lower than those of T-Ag+ astrocytes and GPCs at all time points (P < 0.05, ANOVA with post-hoc comparisons as well as linear regression of T-Ag+ cell density on length of infection; Figure 4C). Interestingly, while the T-Ag+ infection rate of both GPCs with dense aggregations of VP1+ astrocytes, VP1+ oligodendroglia were rare, despite overt oligodendrocytic loss and demyelination (Figure 3, A-D). By 12 weeks postinfection, demyelination was widespread and associated with regions of focal gliosis embedded within demyelinated loci. At these longer postinfection time points, diffuse hypomyelination of the callosa and capsules of infected chimeric Rag2−/− Mbpsh/+ mice was noted (Figure 3, C and D); oligodendrocytic VP1 expression remained unusual, but T-Ag immunolabeling revealed large numbers of infected oligodendrocytes (Figure 3D). Human chimeric controls by that time point exhibited dense human GPC-derived myelination (Figure 3E).

These observations suggest that the principal direct targets of JCV infection in the adult CNS are astrocytes and their progenitors, as cellular expression of the VP1 capsid protein, which is expressed by mature postreplication virions, was largely limited to astroglia and GPCs. Thus, astrocytes and GPCs may be the principal reservoirs for intracerebral viral propagation. In contrast, VP1+ human oligodendrocytes were uncommon, and inevitably appeared dying or pyknotic (Figure 2A); most infected oligodendroglia that could be identified as such in vivo were T-Ag+, but VP1+. This finding indicated that oligodendroglia are initially infected, but die or are lost before the VP1-identifiable completion of viral replication.

JCV infection in vivo spreads in different cell types at different rates. As a result of the human-selective nature of JCV infection, and the lack of early or phenotype-specific radiographic surrogates, the dynamics of viral propagation in the infected CNS remain unknown. We thus investigated the pattern of JCV spread in human glial chimeras, as a function of time after infection. We tracked the expansion and spread of both infected glia and of the fraction harboring replicating virus by immunostaining for T-Ag and VP1, respectively. Both T-Ag+ and VP1+ human cells were progressively more numerous and widespread as a function of time after infection, with infection progressing from the site of viral injection at 4 weeks to include much of the central white matter at 12 weeks (Figure 4A). Notably, despite ample evidence of astrocytic viral replication, as defined by VP1 expression, by astrocytes and GPCs alike (Figure 4, B, D, and E), a high proportion of T-Ag+ glia remained viable but VP1+; indeed, the ratio of T-Ag+ glia to VP1+ glia increased with time over the 12-week observation period (Figure 4B), suggestive of an accelerated rate of infection. While these T-Ag+VP1+ infectants included oligodendrocytes, most were astroglial; both the density and relative proportions of T-Ag+MBP+ oligodendrocytes were significantly lower than those of T-Ag+ astrocytes and GPCs at all time points (P < 0.05, ANOVA with post-hoc comparisons as well as linear regression of T-Ag+ cell density on length of infection; Figure 4C). Interestingly, while the T-Ag+ infection rate of both GPCs with dense aggregations of VP1+ astrocytes, VP1+ oligodendroglia were rare, despite overt oligodendrocytic loss and demyelination (Figure 3, A-D). By 12 weeks postinfection, demyelination was widespread and associated with regions of focal gliosis embedded within demyelinated loci. At these longer postinfection time points, diffuse hypomyelination of the callosa and capsules of infected chimeric Rag2−/− Mbpsh/+ mice was noted (Figure 3, C and D); oligodendrocytic VP1 expression remained unusual, but T-Ag immunolabeling revealed large numbers of infected oligodendrocytes (Figure 3D). Human chimeric controls by that time point exhibited dense human GPC-derived myelination (Figure 3E).
JCV does not require oligodendrocytes for viral infection and spread. Since astroglia appeared sufficient for both viral infection and propagation, we next asked whether oligodendrocytes were even necessary for viral spread in vivo. To this end, we injected Mad-1 JCV into the callosa of 16-week-old immunodeficient but myelin WT human glial chimeric Rag1–/– mice (n = 5); these normally myelinated mice recruit few, if any, oligodendrocytes from the engrafted progenitor pool, so that their human cell complement remains limited to GPCs and astrocytes (7). At 12 weeks after viral injection (i.e., 28 weeks of age), the expansion of VP1+ infected cells within these chimeric Rag1–/– hosts was grossly similar to that of human glial Rag2–/– Mbpsh/si mice (Figure 5A; compare with Figure 4A). Importantly, however, the compartmental pattern of viral spread differed in the recipient phenotypes. In Rag1–/– chimeras, in which human donor cells integrated only as astrocytes and...
GPCs, but not oligodendrocytes, JCV infection predominated in the cortex (Figure 5, B–E). This sharply contrasted the pattern of viral spread in the chimeric Rag2−/− Mbpshi/shi mice, in which human cells also engrafted as oligodendrocytes and fibrous astrocytes, and in which JCV infection was noted to preferentially spread in the white matter (Figure 5F). These observations indicated that oligodendroglia are not necessary for JCV propagation in vivo and that astroglia are sufficient to support viral infection and spread. Thus, these data strongly support the notion that astrocytes and GPCs serve as the principal reservoirs for JCV in vivo.

**JCV-infected oligodendrocytes enter the cell cycle.** Polyoma large T-Ag can trigger cell cycle entry and S-phase initiation by various mitotically quiescent somatic cell types, via binding to retinoblastoma protein (Rb); the resultant progression to S-phase both permits and accelerates viral replication (16). On that basis, we next asked whether cell cycle initiation occurs in JCV-infected oligodendrocytes in PML, and if so, whether the induction of cell cycle in postmitotic human oligodendroglia is sufficient to trigger their death. We immunolabeled infected oligodendrocytes in the engrafted Rag2−/− Mbpshi/shi mouse for the mitosis-associated antigen Ki67 and found that 31.0% ± 8.4% of infected mature MBP+ oligodendrocytes were indeed Ki67+, whereas no Ki67+ MBP+ oligodendrocytes were found in matched uninfected controls (Figure 6, A and B).

To further investigate the relationship of JCV infection to aberrant oligodendrocytic cell cycle entry, we then infected cultured oligodendrocytes derived from CD140a+ human fetal GPCs. The plated GPCs were differentiated in vitro into O4+ oligodendroglia over 7 days, then infected with Mad-1 JCV at 10⁵ genome equivalents per cell (GE/cell). For each experiment, 4 matched runs were performed, each in triplicate for a total of 12 scored wells, which represented a minimum of 2,000 cells per group. When assessed at 5 DPI, 26.5% ± 2.2% of O4+ oligodendrocytes expressed T-Ag (Figure 6C), whereas only 1.3% ± 0.6% expressed VP1. When reassessed at 10 DPI, 58.4% ± 2.0% of the T-Ag+ JCV-infected O4+ oligodendrocytes coexpressed Ki67, indicative of their aberrant

**Figure 3. JCV infection of human glial chimeras triggers both focal and diffuse demyelination.** (A and B) At 4 weeks after viral infection, focal regions of demyelination (A, arrows) and infection-associated astrogliosis (B, arrow) were noted in the forebrain white matter of infected mice, typically in discrete foci abutting the callosal wall of the lateral ventricle. hGFAP, human GFAP. (C and D) By 11 weeks after infection, diffuse hypomyelination of the callosa and capsules of infected chimeric mice was noted. (E) Uninfected human chimeric controls by 20 weeks after transplantation exhibited dense GPC-derived myelination, as did JCV-injected non-xenografted murine controls (not shown). hN, human nuclear antigen. Scale bars: 200 μm (A and C); 100 μm (B, D, and E).
entry into cell cycle; conversely, uninfected T-Ag–
oligodendrocytes in the same cultures exhibited no
appreciable Ki67 expression (Figure 6D). These
findings support the in vivo observation of Ki67+MBP+
oligodendroglia in JCV-
injected human glial chi-
meric Rag2–/– Mbpshi/shi
mice (Figure 6, A and B) and sug-
gest that otherwise-post-
mitotic human oligoden-
droglia may be aberrantly
induced into cell cycle entry
by JCV infection.

JCV-induced cell cycle
entry is associated with oligo-
dendrocytic death. We next
asked whether the T-Ag–
associated induction of
oligodendrocytic cell cycle
entry is sufficient to trigger
oligodendrocytic death,
since ectopic cell cycle
entry has been associated
with cell death in a variety
of otherwise-postmitotic
phenotypes. In particular,
an analogous process of cell
cycle activation–induced
death has been described
extensively in neurons, in
which it has been explored
as a mechanism of neu-
rodegenerative cell loss
(17–19), and apoptotic oligo-
dendrocytic death has been
observed in response to JCV
(20, 21).

In vitro, we found that
the number of viable O4 +
oligodendrocytes was sig-
ificantly decreased at 10 DPI
with type 2A JCV
compared with other-
wise-matched uninfected
controls (Figure 6E); the
diminished oligodendro-
cytic numbers of infected
cultures were accom-
panied by a significant
increase in the number
of infection-associated
dying oligodendrocytes, as
defined by TUNEL (Figure

Figure 4. Viral propagation exhibits cell type–selective spread. JCV spread in vivo was tracked by immunostaining
human glial chimeric Rag2–/– Mbpshi/shi brains for both T-Ag and VP1, each as a function of time after infection. In these
chimeric Rag2–/– Mbpshi/shi mice, a large proportion of oligodendrocytes, as well as GPCs and astrocytes, were human.
(A) Sagittal sections of 3 different infected chimeras at each of 3 time points; individual VP1+ cells are dot-mapped.
VP1+ human cells became progressively more widespread with time, with JCV infection progressing from the site of viral
injection to include much of the forebrain white matter by 12 weeks postinfection, with marked cortical spread by that
point as well. (B) T-Ag+ and VP1+ cells, representing all JCV-infected cells and those in which viral replication has occurred,
respectively, both accumulated as a function of time. (C) The number of T-Ag+ astrocytes (GFAP+) and GPCs (NG2+)
was significantly higher than that of T-Ag+ oligodendroglia (MBP+) at all time points examined (P < 0.01, repeated-measures
1-way ANOVA). Furthermore, the in vivo rates of accumulation of T-Ag+ astrocytes and GPCs (reflecting the rate of
infection among each cell type, estimated by regression line slope) were each significantly higher than that of oligo-
dendrocytes (P > 0.01, linear regression). (D–F) Despite their marked differences in T-Ag–defined infectivity and spread,
astrocytes and oligodendrocytes did not differ in their rates of accumulation of VP1+ infectants, likely reflecting the rapid
lytic loss of cells at that stage. *P < 0.05; **P < 0.01; ***P < 0.001.
indicate that the vast majority of oligodendrocytes killed by JCV expressed T-Ag at 10 DPI, only 4.6% ± 0.3% expressed VP1 (P < 0.001, n = 4 each; Figure 6, G and H). These in vitro data indicate that the vast majority of oligodendrocytes killed by JCV infection die in association with T-Ag expression, never progressing to the point of VP1-defined viral replication. Furthermore, in JCV-infected human glial chimeras, we identified sporadic apoptotic oligodendroglia by TUNEL labeling in vivo and found that a large proportion of these TUNEL+O4+ oligodendroglia expressed the mitotic marker Ki67, indicating that their deaths occurred in temporal association with aberrant cell cycle entry. Such apoptotic loss was not observed in infected astrocytes, which instead assumed the hypertrophic appearance of infected pre-lytic cells prior to death. Together, these data strongly suggested that the oligodendrocytic death that ensues after JCV infection is primarily apoptotic and occurs in response to T-Ag–triggered forced cell cycle entry, rather than to replication-associated cytolysis.

Cell cycle arrest at the G2/M transition in astrocytes and GPCs. Polyoma viral replication requires S-phase progression on the part of infected host cells. In particular, previous studies had revealed that JCV genome replication may be facilitated by virally induced cell cycle arrest in G2, prior to the G2/M transition (23). In light of the apparent delay in viral replication in human oligodendroglia, relative to astrocytes and GPCs, we next asked whether infected astrocytes and oligodendrocytes differ in their efficiency of S/G2 traversal.

Since our data indicated that astrocytes and GPCs are the principal vectors of viral spread in vivo, we first investigated the cell cycle status of JCV-infected astroglia by focusing on cyclin B1, which is normally expressed in the cytoplasm in G2 and enters the nucleus only at the initiation of M-phase. Among cells infected with type 2A JCV, T-Ag+ glia expressed nuclear cyclin B1, regardless of their mitotic stage (Figure 7, A–D). In GPCs as well as in astrocytes, cyclin B1 immunoreactivity was localized to the hypertrophic nuclei of infected GPCs (Figure 7, A and E). Furthermore, DAPI staining revealed the frequent presence of T-Ag+ JCV-infected cells with nuclear cyclin B1 that were not mitotic (Figure 7, C and D), which suggests that JCV infection was associated with cell cycle arrest.

To further define the possibility of phenotype-selective cell cycle arrest by JCV, we investigated the state of p53 phosphorylation in JCV-infected human oligodendrocytes, GPCs, and astrocytes. Because p53 is phosphorylated at Ser15 when DNA damage is detected, phospho-p53(Ser15) expression may be used as a marker of DNA damage, as well as its associated cell cycle arrest at G2/M (23–25). We found that a significantly higher proportion of T-Ag+ astrocytes coexpressed phospho-p53(Ser15) than did uninfected T-Ag+ cells (Figure 7, E and F). Similarly, among CD140a+ GPCs infected with type 2A JCV, 36.1% ± 6.1% expressed phospho-p53(Ser15), while only 3.2% of uninfected T-Ag+ GPCs expressed phospho-p53(Ser15) (P < 0.001; Figure 7, G and H). The expression of phospho-p53(Ser15) by T-Ag+...
marked accumulation of cells in G2/M relative to their uninfected controls ($P < 0.001$; Supplemental Figure 2A). Interestingly, a fraction of these infected astrocytes appeared hyperploid, suggestive of ongoing DNA replication in infected astroglia, despite their relative cell cycle arrest (Supplemental Figure 2B). Together, these results suggest that JCV infection of human glia triggers phosphorylation of p53 at Ser15 with concomitant cell cycle arrest at G2/M. Whereas in oligodendrocytes this event appeared to trigger apoptotic cell death, in astrocytes and GPCs it was associated with viral replication leading to cell lysis.

JCV VP1 rapidly mutates in vivo. In PML, point mutations in the gene encoding VP1 capsid have been reported at multiple sites of the sialic acid binding region, yet neither the genesis nor the pathogenic role of these mutations has been clear (26, 27). Because the propagation and spread of JCV in the human glial chimeric Rag2<sup>−/−</sup> Mbp<sup>shi/shi</sup> brains was so robust, we next asked whether JCV mutation might be identified during its replication and spread in this system. To assess viral evolution during active infection in vivo, we sampled 3 sections from each of 5 JCV-infected brains from mice that had been killed 3–11 weeks after viral infection; all mice had been neonatally implanted with human GPCs and were given intracallosal injections of Mad-1 JCV between 4 and 16 weeks of age. Of the 5 mice, 4 were Rag2<sup>−/−</sup> Mbp<sup>shi/shi</sup> (in which donor human GPCs, astrocytes, and oligodendrocytes coexisted) and 1 was Rag1<sup>−/−</sup> (chimeric only for human donor-derived astrocytes and GPCs). TA PCR cells was even more pronounced in O4<sup>+</sup> oligodendrocytes, among which the majority of T-Ag<sup>+</sup> cells expressed phospho-p53(Ser15) (Figure 7, I and J). Indeed, among T-Ag<sup>+</sup>O4<sup>+</sup> oligodendroglia, 83.6% ± 0.9% ($n = 4$) were phospho-p53(Ser15)<sup>+</sup>, compared with 1.3% ± 0.8% of uninfected T-Ag<sup>−</sup>O4<sup>+</sup> cells in the same plates ($P < 0.001$, 2-tailed Student’s $t$ test). Together, these data strongly suggest that JCV infection was associated with G2/M checkpoint arrest, in all 3 glial phenotypes assessed.

To confirm the possibility of T-Ag-associated mitotic arrest, we next conducted cell cycle analysis of JCV-infected human astroglia, which were derived from GPCs exposed to high serum for 10 days, then exposed to JCV and analyzed 14 days later. We noted that the JCV-infected T-Ag<sup>+</sup> astrocytes indeed exhibited the genesis nor the pathogenic role of these mutations has been clear (26, 27). Because the propagation and spread of JCV in the human glial chimeric Rag2<sup>−/−</sup> Mbp<sup>shi/shi</sup> brains was so robust, we next asked whether JCV mutation might be identified during its replication and spread in this system. To assess viral evolution during active infection in vivo, we sampled 3 sections from each of 5 JCV-infected brains from mice that had been killed 3–11 weeks after viral infection; all mice had been neonatally implanted with human GPCs and were given intracallosal injections of Mad-1 JCV between 4 and 16 weeks of age. Of the 5 mice, 4 were Rag2<sup>−/−</sup> Mbp<sup>shi/shi</sup> (in which donor human GPCs, astrocytes, and oligodendrocytes coexisted) and 1 was Rag1<sup>−/−</sup> (chimeric only for human donor-derived astrocytes and GPCs). TA PCR
Figure 7. Cell cycle arrest at G2/M in infected glia. T-Ag+ glia expressed the mitosis-associated nuclear protein cyclin B1, as well as the DNA damage and cell cycle arrest-associated phospho-p53(Ser15), regardless of their mitotic stage. (A and B) Vehicle-treated and uninfected (T-Ag−) GPCs expressed intranuclear cyclin B1 only when mitotic and in M phase (the latter as assessed by DAPI; arrows), whereas the nuclei of JCV-infected (T-Ag+) GPCs admitted cyclin B1 in a temporally promiscuous fashion (arrowheads). (C) Nuclear phospho-p53(Ser15) and cyclin B1 were coexpressed by mitotically arrested infected astrocytes, but not by uninfected astrocytes. (D) Like control GPCs, uninfected astrocytes (T-Ag−GFAP+) expressed intranuclear cyclin B1 only in M phase, whereas JCV-infected astrocytes expressed nuclear cyclin B1 even when not dividing. (E and F) JCV-infected astrocytes (T-Ag+GFAP+) coexpressed phospho-p53(Ser15), associated with G/2M arrest, whereas neither vehicle-treated nor T-Ag− astroglia in infected cultures did so to any significant degree. (G and H) Similarly, JCV-infected GPCs (T-Ag+CD140a+) coexpressed phospho-p53(Ser15), as well as did infected oligodendrocytes (T-Ag+O4+) (I and J); for both oligodendrocytes and their progenitors, T-Ag+ cells were significantly more likely to express phospho-p53(Ser15). All cultures were assessed at 10 DPI with type 2A JCV (Mad-1 NCCR). Scale bars: 20 μm. *P < 0.05; ***P < 0.001.
cloning was used to clone and sequence JCV VP1 DNA from a total of 32 viral clones per sampled section, or 96 per mouse. The VP1 segment of each clone was sequenced and aligned with WT Mad-1 JCV, whose sequence was validated and confirmed in matched aliquots of the infected virus. Among the 480 clones sequenced from the 5 JCV-injected mice, 155 (32%) VP1 genomic mutations were noted compared with the WT Mad-1 sequence; 125 of these yielded mutations in protein sequence. Of these mutants, only 15 distinct loci were represented twice or more in the overall set (Supplemental Table 2); these included 2 mutations — S123C and D66G — which have been described previously in JCV isolated from patients with active PML (26, 27). Each of these lies within the sialic acid binding site of VP1, which is particularly notable as VP1 mutants may lose sialic acid dependence for their binding to host cells; this suggests that specific JCV VP1 mutants may acquire selective advantage during host infection (26). This in turn suggests that capsid protein mutations occurring during viral propagation may dynamically shift the infectivity and phenotypic specificity of JCV in vivo over the course of a single host’s infection.

**VP1 mutants are infective, but show no phenotypic preferences.** On the basis of these observations, we next asked whether JCV mutants carrying PML-associated VP1 mutations could infect human glia as well as parental JCV, and if so, whether their relative infectivities differed in either virulence or phenotypic specificity. We therefore assessed the infectivities of 3 VP1 mutations of type 2A JCV (all with PML-associated Mad-1 NCCR; see Methods) both in vitro and in vivo. These VP1 capsid mutants included L55F, K60E, and S269F, each isolated from a different PML patient. We first assessed each mutant in vitro and found that each robustly infected human oligodendrocytes, astrocytes, and GPCs (Supplemental Figure 3).

We next assessed the in vivo infectivities of the 2 most frequent PML-associated mutations, L55F and S269F. Either WT VP1 JCV or mutant VP1 type 2A JCV was injected into the corpus callosum of human glial Rag2–/– Mbp+chimeric chimeras at 14 weeks of age, and mice were killed 5 weeks later. Histological analysis revealed that each mutant elicited robust infection in the host, with a recapitulation of both glial infection and local demyelination. At the single time point assessed, no overt differences were noted in the respective infectivities of GPCs, astrocytes, or oligodendrocytes by WT VP1 JCV relative to the 2 VP1-mutant variants (Supplemental Figure 4); all 3 viruses manifested robust infection in the human glial chimeric Rag2–/– Mbp+chimeric mice.

**Discussion**

In this study, we used human glial chimeric mice to establish an in vivo model of JCV viral infection and demyelination, mimicking the salient features of PML. We found that in neonatally engrafted Rag2–/– Mbp+chimeric mice (chimeric for human oligodendrocytes as well as astrocytes), oligodendrocytic death and demyelination followed astrocytic infection. In vitro, JCV infection of astrocytes was significantly more rapid and efficient than that of oligodendrocytes, whereas in vivo, JCV appeared to propagate primarily via GPCs and astrocytes, and much less robustly so in central oligodendrocytes. Indeed, astrocytes proved sufficient for viral propagation in vivo, as shown by rapid and robust viral spread in Rag2–/– mice chimeric only for human GPCs and astrocytes, and utterly lacking human oligodendrocytes.

While human oligodendrocytes exhibited much less frequent viral replication than did astrocytes and progenitors, their infection-associated loss and concomitant demyelination was profound; all macroglial phenotypes were targeted and lost after intracerebral injection of JCV. Yet whereas astrocytic death was associated with cellular lysis in the setting of viral replication and spread, oligodendrocytic death was instead presaged by the aberrant cell cycle entry of these otherwise-postmitotic cells, leading to their arrest in G2 and subsequent apoptotic death. Indeed, this finding provides a mechanistic base for previous observations of apoptotic death by JCV-infected oligodendroglia (20, 28). The oligodendrocytic loss and demyelination of JCV-infected human glial chimeras appeared to result from T-Ag–dependent cell cycle induction leading to oligodendrocytic death before viral replication. As a result, when assessed at 5 weeks postinfection, a large proportion of T-Ag+ oligodendrocytes coexpressed Ki67, while oligodendrocytic expression of the replication-associated VP1 protein was uncommon. Our data are therefore suggestive of viral propagation and amplification in an astrocytic reservoir, followed by oligodendrocytic infection, apoptotic death, and demyelination, but with little oligodendroglial viral replication. Although we posit that this concept reflects the typical pattern and pathobiology of JCV’s spread in adult humans, it is important to note that the astrocytic and GPC predominance of JCV infection in these brains may also reflect the unique environment of these human glial chimeras; one might readily envision mechanisms by which the relative infectivities of astrocytes and oligodendrocytes might be influenced by cell type–specific adaptations of the human donor cells to the murine brain environment.

Importantly, viral spread within infected brains was associated with rapid and progressive mutation, presumably within the astrocytic reservoir of infection. This process of serial and progressive mutation may provide a selective advantage to the most virulent viral mutants within individual brains, and thus result in the acceleration of viral spread and cytopathogenicity with time. One might then anticipate the emergence and selection of dominant JCV mutants with time during disease progression in any given patient. While JCV mutations have been noted to arise during the course of disease and have been well documented in VP1 (26, 27), mutation in JCV’s noncoding regulatory regions may be especially critical to disease progression (29–31). Together, these observations suggest that the clonal selection of more infective mutants may occur naturally in human hosts (8); if so, such clonal evolution might account for the terminal acceleration of demyelination often observed in PML patients.

T-Ag can induce aberrant cell cycle entry and S-phase initiation in a variety of somatic phenotypes, through its binding to the tumor suppressor retinoblastoma protein (Rb) and consequent derepression of Rb targets (16, 32–35). Whereas some mitotic phenotypes may undergo neoplastic transformation by this process (and the polyomaviruses have been causally linked to oncogenesis in various species and cell types; refs. 36–41), in postmitotic phenotypes, as in human oligodendrocytes, Rb derepression may instead trigger p53-dependent apoptotic cell death (18). Our present data thus suggest that JCV-induced T-Ag may initiate apoptotic oligodendrocytic death via aberrant cell cycle induction, followed by p53-dependent apoptotic cell death before viral replication can be
completed. While our in vitro and in vivo data collectively suggest that this is the dominant mechanism of JCV-induced oligodendrocytic death, a minority of infected oligodendroglia did progress to viral replication and VP1 expression, which suggests that at least some oligodendroglia may activate mechanisms for apoptotic escape, such as the expression of apoptosis inhibitors (including survivin), which may dominate in astroglia (28). It remains unclear why some JCV-infected oligodendroglia progress to viral replication, whereas most die before reaching that stage, although we posit that this might be a function of the developmental stage at which individual oligodendroglia — or their progenitors — are infected.

In addition to these avenues of death by infected oligodendroglia, our frequent identification of dying oligodendrocytes absent any antigenic evidence of viral infection suggests the concurrent incidence of additional mechanisms for oligodendrocytic loss in JCV-infected brains. Recent studies have highlighted the dependence of oligodendrocytes on local astrocytes (42) and that of neurons upon oligodendroglia (43, 44). Given the marked astroglial pathology so evident in JCV-infected brains, the withdrawal of metabolic support of oligodendrocytes by infected astroglia, as well as the latter’s potential paracrine cytotoxicity (42), might contribute substantially to both oligodendrocytic loss and its associated neuropathology. Oligodendrocytic loss and demyelination in PML may then represent secondary events, reflecting a combination of paracrine toxicity by infected astroglia, loss of astrogial support of local oligodendrocytes, and apoptotic oligodendrocytic death after direct infection; complicating matters further, each of these mechanisms may be dynamically modulated by concurrent JCV mutation, occurring within a contiguous astrocytic reservoir of virus.

Besides identifying astrocytes and their progenitors as principal substrates for JCV propagation in vivo, with oligodendrocytic death a secondary consequence of viral propagation, this astroglial-centric view of PML pathogenesis may have significant clinical implications for both presentation and treatment of disease. Patients with PML frequently manifest encephalopathic confusion and cognitive deficits long before frank radiographic evidence of demyelination is noted. Our results suggest that the clinical deterioration in these patients may reflect progressive astrocytic dysfunction, especially given the strong influence of astrocytes on synaptic coordination and plasticity (7, 45, 46). Even a profound degree of astrocytic pathology may not have been previously noted in PML patients, since MRI of the brain is highly biased toward identifying signal abnormalities in the white matter; contemporary MRI has been relatively insensitive to gray matter; contemporary MRI has been relatively insensitive to gray matter; contemporary MRI has been relatively insensitive to gray matter disruption. Similarly, little focused investigation of astrocytes has been performed in studies of human pathological samples, which have emphasized oligodendrocytic loss and demyelination (21, 47–51), although the early infection of astrocytes in PML has previously been noted (52, 53). Together, our present results suggest that astrocytes may be both necessary and sufficient for JCV infection of the brain and that disease-associated astrocytic dysfunction and loss may be at least as important to the neurological deterioration of JCV-infected patients as their progressive demyelination. More broadly, our findings also introduce the human glial chimeric Rag2−/− Mbp−/−/Sce mouse brain as a unique preparation by which the natural history of pathogenesis specific to the human brain may be assessed in vivo, both longitudinally and in real time, thereby providing fundamentally new opportunities for their mechanistic dissection and therapeutic targeting.

**Methods**

**Tissue preparation.** Human fetal brain tissue was obtained from aborted fetuses (gestational age, 16–22 weeks) under protocols approved by the University of Rochester-Strong Memorial Hospital Research Subjects Review Board. Briefly, cortical tissues were minced and dissociated using papain (Worthington) and DNase (Sigma-Aldrich) and immunoselection of A2B5 (clone A2B5-105, ATCC) (6), or for the more specific CD140α phenotype, using anti-human CD140α (clone oR1; BD Biosciences) followed by anti-mouse IgG2a (Miltenyi Biotech) (14). A2B5/PSA-NCAM+ cells were used for all in vivo experiments, whereas in vitro experiments were done primarily with CD140α−; the latter comprise the fraction of A2B5+/PSA-NCAM− cultures that includes all potentially oligogenic GPCs, while largely excluding committed astroglia. After MACS isolation, the cells were maintained in DMEM/F12/N1 supplemented with 20 ng/ml PDGF-AA (PeproTech Inc.) and 10 ng/ml FGF-2, then transplanted into the brains of neonatal mice within 3 days of sorting.

For preparing specific phenotypes, GPCs were obtained by CD140α sorting, while oligodendroglia were then derived from these GPCs by culture for 1 week in media supplemented with T3 (Sigma-Aldrich) and IGF-1 (Sigma-Aldrich) (14, 56). Astrocytes were isolated from the tissue dissociates using MACS targeting the astrogial hyaluronate receptor CD44 (57), using conjugated microbeads (Miltenyi Biotech; clone DB105) according to the manufacturer’s instructions.

**Viral construction.** Type 1A rearranged NCCR JCV genome (Mad-1; GenBank accession no. NC_001699) in the Bluescript plasmid vector was a gift of R. Frisque (Pennsylvania State University, University Park, Pennsylvania, USA). Type 2A VP1 archetype NCCR JCV genome (type 2A; GenBank accession no. AY121915) was synthesized in 3 fragments (GeneArt) and subsequently ligated to yield the full-length type 2A JCV genome, cloned in an E. coli plasmid. To create the type 2A rearranged viral genome, type 2A JCV NCCR was replaced with rearranged NCCR of Mad-1, by exchanging a 416-bp NcoI fragment from the archetype genome with 425-bp NcoI fragments of pBS–Mad-1. Site-directed mutagenesis (QuickChange; Agilent Technologies) was performed on this rearranged type 2A vector in order to incorporate the VP1 mutations L55F (type 2A 55F VP1 virus), K60E (type 2A 60E VP1 virus), or S269F (type 2A 269F VP1 virus).

**Viral production and purification.** To produce virus, viral genomes were excised from their corresponding replication plasmids with EcoRI restriction endonuclease digestion. The linearized viral genomes were recircularized in a dilute ligation reaction (5 μg/ml) at room temperature overnight, ethanol precipitated and resuspended in TE, and transfected into 293FT cells (Invitrogen) with FuGeneHD (Roche). After 1 week, cells were split into 20 T160 flasks; 2 weeks later, the cultures were collected for virus purification. During these last 2 weeks of virus production, culture medium was added to cultures rather than replaced. Supernatant
was cleared at 2,500 g for 20 minutes, and the pellet then resuspended in 1.20 original volume and used for virus purification. The resuspended pellet was freeze-thawed 3 times to disrupt cells, followed by treatment with benzonase (250 U/ml; Sigma-Aldrich) and neuraminidase (20 U/ml; NEB) at 37°C for 3 hours, to aid in dissociation of viral particles from cellular debris. At that point, detergents including 0.1% deoxycholate and 0.5% TritonX-100 were added, and incubation continued for another hour. The resultant suspension was spun at 2,500 g for 30 minutes at 4°C, the pellet discarded, and the supernatant loaded onto 30% sucrose in low-salt buffer (10 mM HEPES pH 7.9; 1 mM CaCl2; 1 mM MgCl2; 5 mM KCl), then centrifuged using a SW28 rotor at 140,000 g for 3 hours at 4°C. The resultant pellet was soaked in high-salt buffer (10 mM HEPES pH 7.9; 1 mM CaCl2; 1 mM MgCl2; 5 mM KCl; 0.8 M NaCl) overnight, then resuspended and respun through 30% sucrose. The final pellet was again soaked overnight in high-salt buffer, resuspended, and then aliquoted and frozen at –80°C. Final JCV preparations for both Mad-1 and its derived VPI-mutant forms were in the range of 1.6 × 10^12–2.2 × 10^13 GE/ml.

**Viral sequencing.** JCV VPI was sequenced from a sample of infected cells identified in each infected brain, using the forebrain hemisphere contralateral to that used for histological analysis. Each sampled hemisphere was cut into 12-mm × 1-mm coronal sections. DNA was then isolated from each slice using RecoverAll Total Nucleic Acid Isolation Kit for FFPE Tissues (Life Technologies), and the isolated DNA was used for qPCR with JCV-specific primer probe sets. 100 ng total DNA from the second, fourth, and ninth sections was amplified using the Hercuase II Fusion Enzyme system (catalog no. 600677, Agilent Technologies). The VPI coding region was amplified using full-length VPI specific primers 5’-CCTCAATGGATGTGCGTTT-3’ and 5’-AAAACCAAGGCCCCCT-3’. PCR amplification products were then cloned using the TOPO TA Cloning Kit (Invitrogen), transformed, and plated according to the manufacturer’s specifications. 32 individual colonies for each cloned product (96 colonies per brain) were then screened and sequenced, using an Applied Biosystems 3730XL DNA Analyzer with BigDye Terminator version 3.1 chemistry. As a control, 100 ng viral DNA (Mad-1) prepared from the same virus injected into that mouse brain was amplified and cloned using the same conditions as the DNA prepared from brain tissue (in this, H122Y and H122P mutations were noted relative to Mad-1). 96 individual colonies were sequenced, to allow us to estimate the mutation rate of the starting viral genotype. Coding mutations were identified after translating the DNA sequence and aligning the predicted protein sequence to that of Mad-1.

**Infection in vitro.** CD140a+ GPCs and CD44+ astrocytes were plated at 5,000 cells/cm² on Permanox chamber slides (Thermo Scientific) coated with poly-L-ornithine (Sigma-Aldrich) plus laminin (BD) or 12-mm coverslips coated with poly-l-ornithine (Sigma-Aldrich) plus laminin (BD Biosciences). The cells were infected with JCV in 250 μl medium at 10^6 GE/cell for 2 hours at 37°C. CD44+ MACS-derived astrocytes were maintained in the DMEM/F12/N1-based medium with 1% platelet-depleted FBS (Cocalico Biologicals Inc.) and infected 2 days after plating at 10^5 GE/cell. CD140a+ MACS-derived GPCs were plated in ultra-low-attachment 24-well plates (Corning Inc.) at 10^5 cells/well in Neurobasal medium supplemented with 1× B27, 20 ng/ml PDGF-AA, and 10 ng/ml FGF-2. The following day, the cells were infected with JCV at 10^6 GE/cell for 2 hours.

**Animals and GPC transplantation.** In this study, 2 immunodeficient mouse strains were used: one myelin deficient and the other normally myelinated. Homozygous myelin-deficient shiverer mice (Mbp-shi/shi) were crossed with homozygous Rag2–/– immunodeficient mice (Taconic) to generate a line of myelin-deficient and immunodeficient Rag2–/– Mbp-shi/shi mice. In addition, normally myelinated and immunodeficient Rag1–/– mice were obtained from the Jackson Laboratory. All mice were bred and housed in a pathogen-free environment in accordance with the University of Rochester animal welfare regulations. Newborn pups were transplant- ed within a day of birth, with 200,000–400,000 donor cells delivered across 4 injection sites (6). In all determinations of animal use, group assignment, numbers, experimental design, and description of results in this study, we attempted to follow the ARRIVE reporting guidelines (58).

**Virus administration.** Adult mice were anesthetized with a mixture of ketamine (JHP Pharmaceuticals) and xylazine (Akorn Inc.), in accordance with University of Rochester protocols. JCV, prepared as indicated to a final concentration of 1.6 × 10^12–2.2 × 10^13 GE/ml, was thawed and resuspended in HBSS buffer (Life Technologies) before injection. 1 μl virus was injected bilaterally into the corpus callosum (total, 2 μl; AP, +0.5; ML, ±0.8; DV, -1.4), using a Gastight (Hamilton) syringe.

**Tissue collection.** Larvae of Rag2–/– Mbp-shi/shi mice that had been transplanted neonatally with human cells were injected with Mad-1 virus between 9 and 16 weeks of age. Homozygous Rag2–/– Mbp-shi/shi mice in our colony did not reliably live longer than 20–22 weeks. Accordingly, when infected mice were noted to be moribund, they were euthanized with sodium pentobarbital (Nembutal) and transcardially perfused with HBSS followed by 4% paraformaldehyde/phosphate buffer (PFA/PB). The brains were then extracted from the skull, postfixed for 2 hours in the same fixative, and cryoprotected in a sucrose buffer. Serial sagittal sections were cut at 14 μm on a cryo-Stat (Leica) and mounted on glass slides. Myelin WT Rag1–/– mice were injected with JCV at 16 weeks and sacrificed at 28 weeks of age.

**Immunohistochemistry in culture.** Adherent cells were fixed with 4% PFA/PB and immunolabeled using primary antibodies as follows: mouse anti–T-Ag antibody (1:300 dilution; Pab2003, gift of R. Frisque); mouse anti–large T-Ag antibody (1:50 dilution; Pab416, Calbiochem): rabbit anti–SV40 T-Ag antibody (1:50 dilution; v-300, SantaCruz, known to cross-react with JCV T-Ag); mouse anti–VPI antibody (1:3,000 dilution; PAB97, Biogen); chicken anti–GFAP antibody (1:800 dilution; Chemicon); rabbit anti–CD140a antibody (1:800 dilution; D13C6, Cell Signaling Technology); mouse antiphospho-p53(Ser15) antibody (1:100 dilution; Cell Signaling Technology); rabbit anti–cyclin B1 antibody (1:180 dilution; Cell Signaling Technology); rabbit anti–Ki67 antibody (1:300 dilution; Thermo). Oligodendrocytes were stained as live cells with supernatant from O4 hybridoma (gift of I. Duncan, University of Wisconsin, Madison, Wisconsin, USA) at 10 μg/ml, followed by fixation with 4% PFA/0.1 M PB. CD140a+ GPCs were collected as spheres, fixed with 2% PFA/PB for 10 minutes, immersed in 15% followed by 30% sucrose/PB, cut at 6 μm on a cryostat, mounted on glass slides, and subjected to immunohistochemistry. Alexa Fluor 488, 594, and 647–conjugated goat secondary antibodies against appropriate animal species and Ig classes (Invitrogen) were used at 1:1,000 dilution. The nucleus was counterstained with DAPI at 600 nM.

**Immunohistochemistry in sections.** Slide-mounted sections were rehydrated with 0.1 M PBS and permeabilized and blocked for 1 hour with PBS containing 0.1% Triton X-100 and 10% normal goat serum.
Immunolabeling was performed using the following primary antibodies: mouse anti-human nuclear antigen, clone 235-1 (1:800 dilution; MAB1281, Millipore); mouse anti-VP1 (1:1,000 dilution; PAB597, Biogen); rabbit anti-SV40 VP1 (1:500 dilution; AB53977, Abcam); mouse anti-T-Ag (1:60 dilution; PAB2003, gift of R. Frisque); rabbit anti-SV40 T-Ag, v-300 (1:50 dilution; SC-20800, Santa Cruz); rat anti-MBP (1:25 dilution; ab7349-1, Abcam); mouse anti-human GFAP SMI-211 (1:500 dilution; ADG 050809, Covance); rabbit anti-GFAP (1:800 dilution; ab39322-100, Abcam); mouse anti-human NG2 (1:200 dilution; Mab 2029, Millipore); rabbit anti-NG2 (1:200 dilution; AB5320, Millipore); rabbit anti-Ki67 (1:50 dilution; clone SP6, LabVision); and rabbit anti-CD140a (1:400 dilution; Mab 3174, Cell Signaling Technologies). Alexa Fluor-conjugated secondary antibodies were used at 1:400 dilution (Invitrogen). Slides were coverslipped using Vecta-shield mounting media with DAPI (Vector Labs).

**Image analysis.** The incidence of individual human phenotypes was estimated using the Optical Fractionator Program of Stereo Investigator (MBF Bioscience). Stained sagittal sections were imaged as 7-μm stacks of 7 superimposed optical slices, taken at 0.2-μm intervals in the corpus callosum at x<20, using an Olympus BX51 with Ludl stage. The entire corpus callosum (excluding fimbria) was mapped for each of 2 random sections, either 336–672 μm or 672–1,008 μm from the midline, for each experimental mouse.

**In situ detection of JCV genome.** JCV infection was also detected by DNA in situ hybridization. The slides were incubated with a biotinylated DNA probe for the JCV genome (Enzo Life Sciences) at 2 μg/ml at 95°C for 2 minutes, then at room temperature for 1 hour. The hybridization signal was detected by incubating with fluorescein-labeled avidin (1:400 dilution; Invitrogen).

**Flow cytometric cell cycle analysis.** Cell cycle analysis was performed by flow cytometric evaluation of propidium iodide–exposed cells after immunolabeling for T-Ag. Fetal astrocytes were infected with type 2A VP1 JCV (Mad-1 NCCR) at 10⁴ GE/cell in 6-well plates, passaged twice in 60-mm dishes, then plated into 100-mm dishes. 14 days after inoculation, cells were harvested using Accutase and fixed with 70% ethanol overnight at -20°C. The cells were immunolabeled with rabbit anti-T-Ag polyclonal antibody (1:500 dilution; v-300, SantaCruz) followed by Alexa Fluor 488-conjugated secondary antibody (1:1,000 dilution). DNA content was detected with propidium iodide (4 μg/ml). Flow cytometry was performed using FACS Canto (BD Biosciences), and data were analyzed with FlowJo software (Tree Star). The percentage of cells in each cell cycle was calculated based on the Dean-Jett-Fox model in FlowJo, comparing vehicle-treated and JCV-infected astrocytes.

**Statistics.** Data are provided as mean ± SEM. Both 1- and 2-way ANOVA were performed with Bonferroni corrections for multiple comparisons. All statistical analyses were performed using Prism (GraphPad Software), and a P value less than 0.05 was considered statistically significant.

**Study approval.** Human fetal brain tissue was obtained under protocols approved by the University of Rochester-Strong Memorial Hospital Research Subjects Review Board. Deidentified human fetal brain tissue was obtained within 1 hour of surgical acquisition from the University of Rochester Department of Pathology; no patient identifiers were available to study personnel. All animal protocols were in accordance with University of Rochester animal welfare regulations.

**Acknowledgments**

This work was supported by Biogen Idec, NINDS grant R01NS75345, the New York State Stem Cell Research Program (NYSTEM), and the National Multiple Sclerosis Society. We thank Richard Frisque and Ian Duncan for gifts of antibodies; Margot Brickelmaier, Jeff Thompson, Ken Simon, Wanyong Zeng, Eric Baetscher, Kathryn Doyle, Christopher Tonkin, Michele McAuliffe, and John Anderson of Biogen for technical support; Adam Cornwell for statistical advice and support; and Abdellatif Benraiss for imaging assistance.

Address correspondence to: Steven A. Goldman, Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, New York 14642, USA. Phone: 585.275.9550; E-mail: steven.goldman@urmc.rochester.edu.
RESEARCH ARTICLE


32. Caracciolo V, Reiss K, Khalili K, De Falco G, Gior-